Attenuation of SRC Kinase Activity Augments PARP Inhibitor–mediated Synthetic Lethality in <i>BRCA2</i> -altered Prostate Tumors
Goutam Chakraborty(National Centre for Cell Science), Philip W. Kantoff(Convergent Science (United States)), Michael J. Morris(Dana-Farber Cancer Institute), Yuki Yoshikawa(Hiroshima Prefectural Hospital), Daniel C. Danila, Gwo‐Shu Mary Lee(Dana-Farber Cancer Institute), Ying Z. Mazzu(Memorial Sloan Kettering Cancer Center), Lorelei A. Mucci(American Cancer Society), Konrad H. Stopsack(Memorial Sloan Kettering Cancer Center), Wassim Abida(Memorial Sloan Kettering Cancer Center), Nabeela Khan Patail(Memorial Sloan Kettering Cancer Center), Subhiksha Nandakumar(Memorial Sloan Kettering Cancer Center), Rahim Hirani(New York Medical College), Lina Jehane(Memorial Sloan Kettering Cancer Center), Mohammad Atiq(Memorial Sloan Kettering Cancer Center)
Cited by 21
Related Papers
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
|New England Journal of Medicine|2010|5.5k
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k
Gene expression correlates of clinical prostate cancer behavior
|Cancer Cell|2002|2.5k
Risk of COVID-19 among front-line health-care workers and the general community: a prospective cohort study
|The Lancet Public Health|2020|2.3k